{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:10:24Z","timestamp":1792746624591,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.eururo.2015.04.028","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T04:48:01Z","timestamp":1431492481000},"page":"505-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort"],"prefix":"10.1016","volume":"69","author":[{"given":"Katharina","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Sjoberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders S.","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.04.028_bib0155","doi-asserted-by":"crossref","first-page":"c4521","DOI":"10.1136\/bmj.c4521","article-title":"Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study","volume":"341","author":"Vickers","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2015.04.028_bib0160","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schroder","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.04.028_bib0165","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schroder","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.04.028_bib0170","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the Goteborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.04.028_bib0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2015.04.028_bib0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/1471-2407-10-635","article-title":"A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France","volume":"10","author":"Benchikh","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2015.04.028_bib0185","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/sj.bjc.6605815","article-title":"A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands","volume":"103","author":"Gupta","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2015.04.028_bib0190","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1021\/ac061201+","article-title":"Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab\u2032)2 fragments","volume":"78","author":"Vaisanen","year":"2006","journal-title":"Anal Chem"},{"key":"10.1016\/j.eururo.2015.04.028_bib0195","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","article-title":"Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication","volume":"28","author":"Vickers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.028_bib0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-6-19","article-title":"A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden","volume":"6","author":"Vickers","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.eururo.2015.04.028_bib0205","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1158\/1078-0432.CCR-10-0122","article-title":"A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam","volume":"16","author":"Vickers","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.04.028_bib0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/jnci\/djs486","article-title":"Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations","volume":"105","author":"Haiman","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.04.028_bib0215","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ng.90","article-title":"Multiple newly identified loci associated with prostate cancer susceptibility","volume":"40","author":"Eeles","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2015.04.028_bib0220","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ng.91","article-title":"Multiple loci identified in a genome-wide association study of prostate cancer","volume":"40","author":"Thomas","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2015.04.028_bib0225","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0022-5347(05)00695-6","article-title":"A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis","volume":"175","author":"Nam","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.028_bib0230","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1158\/1078-0432.CCR-06-0625","article-title":"Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy","volume":"12","author":"Reeves","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.04.028_bib0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","article-title":"Histologic grading of prostate cancer: a perspective","volume":"23","author":"Gleason","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2015.04.028_bib0240","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/clinchem\/41.8.1115","article-title":"Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum","volume":"41","author":"Mitrunen","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2015.04.028_bib0245","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1373\/clinchem.2005.050641","article-title":"Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C","volume":"52","author":"Ulmert","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2015.04.028_bib0250","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/clinchem\/47.8.1415","article-title":"Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146","volume":"47","author":"Nurmikko","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2015.04.028_bib0255","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/clinchem\/42.7.1034","article-title":"Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum","volume":"42","author":"Piironen","year":"1996","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2015.04.028_bib0260","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/clinchem\/35.7.1497","article-title":"Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women","volume":"35","author":"Abrahamsson","year":"1989","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2015.04.028_bib0265","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2164\/jandrol.107.003616","article-title":"Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males","volume":"29","author":"Valtonen-Andre","year":"2008","journal-title":"J Androl"},{"key":"10.1016\/j.eururo.2015.04.028_bib0270","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/clinchem\/46.10.1610","article-title":"Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA","volume":"46","author":"Nurmikko","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2015.04.028_bib0275","doi-asserted-by":"crossref","first-page":"djv095","DOI":"10.1093\/jnci\/djv095","article-title":"Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study","volume":"107","author":"Bryant","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.04.028_bib0280","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(14)70361-4","article-title":"Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial","volume":"15","author":"Lane","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.04.028_bib0285","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.eururo.2015.04.028_bib0290","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.eururo.2015.04.028_bib0305","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.028_bib0300","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1464-410X.2009.08793.x","article-title":"Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population","volume":"105","author":"Kaplan","year":"2010","journal-title":"BJU Int"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T03:52:03Z","timestamp":1599018723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815003309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0302283815003309"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.028","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}